TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03322579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon dilatation Eustachian tuboplasty
Description: Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
Study: NCT02907502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Young-child formula with low protein content
Description: Young-child formula with low protein content
Study: NCT02308033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel vehicle
Study: NCT01084044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ulinastatin, saline solution
Description: the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ulinastatin, saline solution
Description: the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin, saline solution
Description: the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
Study: NCT02332486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qingxuan Decoction
Description: In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
Study: NCT01176253

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
Study: NCT02907502

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Young-child formula with protein content similar to that of cow's milk
Description: Young-child formula with protein content similar to that of cow's milk
Study: NCT04630873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: The triceps surae along with the posterior tibialis muscle will be injected. The units that will be injected are the average being injected in our University Clinic. I.e. 50 units for each head of the gastrocnemius muscle- single injection site, 100 units for the soleus muscle- two injection sites and 50 units for the posterior tibialis muscle- single injection site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin
Description: The triceps surae along with the posterior tibialis muscle will be injected. The units that will be injected are the average being injected in our University Clinic. I.e. 50 units for each head of the gastrocnemius muscle- single injection site, 100 units for the soleus muscle- two injection sites and 50 units for the posterior tibialis muscle- single injection site.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: gait analysis
Description: The gait analysis will be performed with two systems. A foot pressure sensitivity walkway (medicapteurs Win-Track), and an IMU network system (RehaGait Pro) using seven IMU's placed in specific anatomical positions. In combination those two systems can provide a wide range of spatiotemporal analytics of gait:

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: gait analysis
Description: The gait analysis will be performed with two systems. A foot pressure sensitivity walkway (medicapteurs Win-Track), and an IMU network system (RehaGait Pro) using seven IMU's placed in specific anatomical positions. In combination those two systems can provide a wide range of spatiotemporal analytics of gait:
Study: NCT02065882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT524 (fibrinogen concentrate from human plasma)
Description: single intravenous infusion
Study: NCT02525562

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon Total Knee System with X3 insert
Description: Total knee replacement

Intervention type: DEVICE
Group type: OTHER
Intervention: Scorpio NRG Total Knee System with X3 insert
Description: Total knee replacement

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon PKR System with X3 insert
Description: Partial Knee Resurfacing

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Knee Replacement
Description: Total Knee Replacement

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Knee Replacement
Description: Total Knee Replacement

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Partial Knee Resurfacing
Description: Partial Knee Resurfacing
Study: NCT00300573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexelvucitabine
Description: nucleoside inhibitor of HIV Reverse Transcriptase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexelvucitabine
Description: nucleoside inhibitor of HIV Reverse Transcriptase
Study: NCT02543164

Intervention type: OTHER
Group type: OTHER
Intervention: REFERENCE: white bread
Description: Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC).

Intervention type: OTHER
Group type: OTHER
Intervention: TEST: b-glucan enriched bread
Description: Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC).
Study: NCT00099320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units \[5 μg\] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units \[10 μg\] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
Study: NCT01136005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dexpanthenol 5% cream
Description: Apply at least two times a day on face, chest and upper arms during the 6 week treatment period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cetomacrogol cream
Description: Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
Study: NCT03998215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria booster vaccination
Description: Participants received intramuscularly in the deltoid muscle one dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
Study: NCT03943121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Steroid-eluting stent implant
Description: After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Without Steroid-eluting stent implant
Description: After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus. And the side without the stent is defined as the control side.
Study: NCT04440163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: N meningitidis groups A, B, C, W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: N meningitidis groups A, B, C, W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: N meningitidis groups A, B, C, W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: N meningitidis groups A, B, C, W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trumenba
Description: Bivalent recombinant lipoprotein 2086 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trumenba
Description: Bivalent recombinant lipoprotein 2086 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trumenba
Description: Bivalent recombinant lipoprotein 2086 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trumenba
Description: Bivalent recombinant lipoprotein 2086 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Meningococcal group A, C, W-135, and Y conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Meningococcal group A, C, W-135, and Y conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Meningococcal group A, C, W-135, and Y conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Meningococcal group A, C, W-135, and Y conjugate vaccine
Study: NCT03339531

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2D radiotherapy
Study: NCT04307225

Intervention type: DEVICE
Intervention: Zenicor
Description: Handheld Thumb ECG monitoring device

Intervention type: DEVICE
Intervention: Zenicor
Description: Handheld Thumb ECG monitoring device
Study: NCT05000918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Okara protein hydrolysate (OPH)
Description: Okara protein hydrolysate (OPH) was a pack of dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight.
Study: NCT01213758

Intervention type: OTHER
Intervention: Measuring liver function by PET/CT
Description: Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
Study: NCT01786694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cma microdialysis catheter placement
Description: the microdialysis catheters are sold by CMA
Study: NCT03760965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT04754919

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transition intervention group
Description: Support and on-going treatment intervention; monitoring the uptake of routine annual diabetes tests and encouraging to access where default observed General specialist diabetes support and provision of education and referral to other specialist healthcare agencies as individual requires

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Post transition group
Description: The previous fifty eligible young people who have transitioned to adult service, will be compared with the active comparator group.
Study: NCT04234373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carb diet
Description: Low Carb diet (max. 130g carbohydrates/d) for 6 months
Study: NCT04389619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Microneedling Radiofrequency
Description: In every patient, each one of the two scars, or each side of a large scar will be assigned to fractional microneedling radiofrequency. Fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz for 5 treatment sessions 4 weeks apart.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Steroid Injection with and without Microneedling
Description: In every patient, each one of the two scars, or the other side of a large scar will be assigned to intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. o Scars treated with intralesional steroids will be subgrouped into two groups, one group treated with only intralesional steroids and the other group treated with intralesional steroids and followed by microneedling. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. Patients will receive 5 treatment sessions 4 weeks apart.
Study: NCT00656019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 0, 2000, 4000, and 6000 IU per day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 0, 2000, 4000, and 6000 IU per day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 0, 2000, 4000, and 6000 IU per day orally
Study: NCT01716507

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retinal Detachment repair
Description: Comparing 23 gauge vs 20 gauge pars plana vitrectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retinal Detachment repair
Description: Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
Study: NCT02732886

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medifoam®
Description: Foam Dressing
Study: NCT01970072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate
Study: NCT01788683

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regenexx SD
Description: stem cell treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: exercise therapy control
Study: NCT01194674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
Study: NCT02095262

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reactive auditory training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive auditory training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive auditory training
Study: NCT02732886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Betafoam®
Description: Foam dressing including Betadine iodine
Study: NCT01079078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study: NCT01966341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT/ Hypnotherapy
Description: The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Management
Description: Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
Study: NCT00665626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium (R935788)
Description: R935788 100 mg tablet, orally, twice-a-day
Study: NCT01970072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosylate
Study: NCT00665626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, twice-a-day
Study: NCT01488071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets, daily, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agomelatine
Description: encapsulated tablets, daily, orally
Study: NCT04071275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mirror therapy
Description: Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
Study: NCT02635477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Behavioral: actigraphy device, adaptive step count algorithm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Behavioral: actigraphy device, adaptive step count algorithm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Behavioral: actigraphy device, step count measurement only
Study: NCT02966067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Device (Experimental)
Description: Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30-gauge Short Hypodermic Needle
Description: Injection of 1.2ml of a standard local dental anaesthetic solution \[1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)\] at a rate of 1 mL/min.
Study: NCT01646476

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered stent (Bona stent pyloric/duodenal covered) insertion
Description: self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered stent (Bona stent, pyloric/duodenal) insertion
Description: Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.